Jump Financial LLC Sells 4,988 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Jump Financial LLC has significantly reduced its stake in IDEXX Laboratories, Inc. by 90.9%, now owning only 500 shares, following a sale of nearly 5,000 shares.
• Several institutional investors increased their stakes in IDEXX Laboratories, including Mutual of America Capital Management LLC with a 79.6% increase, and Golden State Wealth Management LLC which boosted its holdings by over 3,700%.
• Despite insider selling, IDEXX Laboratories reported a positive quarterly earnings performance with EPS of $3.63, exceeding analysts' expectations, and a year-over-year revenue increase of 10.6%.

Jump Financial LLC lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 90.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 500 shares of the company's stock after selling 4,988 shares during the quarter. Jump Financial LLC's holdings in IDEXX Laboratories were worth $210,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. MorganRosel Wealth Management LLC bought a new stake in shares of IDEXX Laboratories in the 1st quarter valued at approximately $26,000. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of IDEXX Laboratories by 55.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock worth $35,000 after buying an additional 30 shares during the last quarter. Colonial Trust Co SC raised its stake in shares of IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after purchasing an additional 39 shares in the last quarter. Bank of Jackson Hole Trust raised its stake in shares of IDEXX Laboratories by 328.6% in the first quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock valued at $39,000 after purchasing an additional 69 shares in the last quarter. Finally, Cornerstone Planning Group LLC raised its stake in shares of IDEXX Laboratories by 108.0% in the first quarter. Cornerstone Planning Group LLC now owns 104 shares of the company's stock valued at $44,000 after purchasing an additional 54 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on IDXX shares. Jefferies Financial Group began coverage on IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target on the stock. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, July 12th. JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research note on Monday, August 4th. Leerink Partners boosted their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $700.00 price target (up previously from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus target price of $649.44.

IDEXX Laboratories Stock Performance

Shares of IDXX traded up $2.55 during mid-day trading on Friday, reaching $642.99. The company's stock had a trading volume of 370,390 shares, compared to its average volume of 413,114. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $688.12. The stock has a market cap of $51.44 billion, a P/E ratio of 53.54, a PEG ratio of 4.16 and a beta of 1.56. The business has a 50-day simple moving average of $593.22 and a two-hundred day simple moving average of $507.11. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. The business had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the firm posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Nimrata Hunt sold 7,143 shares of IDEXX Laboratories stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total value of $4,503,161.49. Following the transaction, the executive vice president owned 18,007 shares in the company, valued at approximately $11,352,153.01. This trade represents a 28.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sharon E. Underberg sold 5,450 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the sale, the executive vice president owned 6,156 shares in the company, valued at $4,011,249.60. This represents a 46.96% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.